Imaging the side effects of CAR T cell therapy: a primer for the practicing radiologist
Chimeric antigen receptor (CAR) T cell therapy is a revolutionary form of immunotherapy
that has proven to be efficacious in the treatment of many hematologic cancers. CARs are …
that has proven to be efficacious in the treatment of many hematologic cancers. CARs are …
[HTML][HTML] More than Just skin-Deep: a review of Imaging's role in guiding CAR T-cell therapy for advanced melanoma
Advanced melanoma is one of the deadliest cancers, owing to its invasiveness and its
propensity to develop resistance to therapy. Surgery remains the first-line treatment for early …
propensity to develop resistance to therapy. Surgery remains the first-line treatment for early …
[HTML][HTML] CAR-T cells and the kidney: insights from the WHO safety database
Background Chimeric antigen receptor T (CAR-T) cells have proven to be a game changer
for treating several hematologic malignancies. Randomized controlled trials have …
for treating several hematologic malignancies. Randomized controlled trials have …
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy
Introduction Acute kidney injury (AKI) frequently develops in patients receiving cancer
therapy and requires a wide differential diagnosis due to possible role of unique cancer and …
therapy and requires a wide differential diagnosis due to possible role of unique cancer and …
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
X Wen, G Xu - OncoTargets and Therapy, 2024 - Taylor & Francis
Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and
have significantly improved the outcomes of relapsed or refractory cancer patients. As …
have significantly improved the outcomes of relapsed or refractory cancer patients. As …
[HTML][HTML] Immune checkpoint inhibitors and renal toxicity
F Bocchi, S Häfliger, S Schmid, D Sidler - Heliyon, 2024 - cell.com
Immune checkpoint inhibitors (ICIs) have transformed the management of a broad spectrum
of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These …
of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These …
[HTML][HTML] From spear to trident: upgrading arsenal of CAR-T cells in the treatment of multiple myeloma.
J Zhao, M Zheng, L Ma, T Guan, L Su - Heliyon, 2024 - cell.com
Multiple myeloma (MM), marked by abnormal proliferation of plasma cells and production of
monoclonal immunoglobulin heavy or light chains in the majority of patients, has traditionally …
monoclonal immunoglobulin heavy or light chains in the majority of patients, has traditionally …
CAR-T Cell Therapy and the Onco-Nephrologist
MA Salvino, A Mussetti, D Rizky, MD Pena… - Frontiers in …, 2024 - frontiersin.org
Cell therapy, specifically the revolutionary Chimeric Antigen Receptor (CAR)-T Cell therapy,
has transformed the landscape of oncology, making substantial strides in practical treatment …
has transformed the landscape of oncology, making substantial strides in practical treatment …
[HTML][HTML] Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review
A Jaiswal, K Shergill, K Boppana, NE Almansouri… - Cureus, 2024 - ncbi.nlm.nih.gov
The most recent advancements in cancer therapy center on efficiently and conveniently
enhancing a patient's natural immune system. Immune checkpoint inhibitors (ICIs) are …
enhancing a patient's natural immune system. Immune checkpoint inhibitors (ICIs) are …